Inhibikase Therapeutics, Inc. (IKT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 38.24M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 19.96M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -65.44M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $38.24M | (m) | $19.96M | $-65.44M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $30.12M | (m) | $18.83M | $-55.22M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $29.79M | (m) | $15.31M | $-51.97M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $30.63M | $0.00 | $18.68M | $-51.13M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $27.17M | $0.00 | $14.31M | $-44.19M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $24.97M | $0.00 | $10.13M | $-38.40M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $17.21M | $0.00 | $8.14M | $-28.59M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $13.02M | $1.00 | $354.40K | $-20.06M | (m) | 1301996200.00% | 35440400.00% | (m) | (m) |
| 2024-06-30 | $12.06M | $79.57K | $336.16K | $-19.01M | (m) | 15150.99% | 422.47% | (m) | (m) |
| 2024-03-31 | $13.52M | $195.98K | $430.31K | $-20.16M | (m) | 6896.37% | 219.57% | (m) | (m) |
| 2023-12-31 | $13.62M | $260.50K | $500.15K | $-20.09M | (m) | 5227.75% | 191.99% | (m) | (m) |
| 2023-09-30 | $13.67M | $324.07K | $478.26K | $-20.02M | (m) | 4218.13% | 147.58% | (m) | (m) |
| 2023-06-30 | $13.43M | $251.79K | $450.27K | $-19.77M | (m) | 5332.12% | 178.83% | (m) | (m) |
| 2023-03-31 | $11.87M | $141.93K | $458.19K | $-18.20M | (m) | 8364.77% | 322.83% | (m) | (m) |
| 2022-12-31 | $12.03M | $123.44K | $458.15K | $-18.13M | (m) | 9749.66% | 371.15% | (m) | (m) |
| 2022-09-30 | $12.37M | $61.82K | $623.63K | $-18.84M | $163.00 | 20012.11% | 1008.82% | -115552.73× | Reported |
| 2022-06-30 | $12.54M | $382.99K | $874.26K | $-18.79M | $320.00 | 3275.31% | 228.28% | -58728.24× | Reported |
| 2022-03-31 | $11.94M | $1.74M | $1.06M | $-16.78M | $8.13K | 686.66% | 61.17% | -2063.89× | Reported |
| 2021-12-31 | $11.36M | $3.10M | $1.53M | $-14.77M | $19.92K | 366.35% | 49.41% | -741.16× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $893.80K | $698.47K | $573.70K | $-2.82M | $29.40K | 127.97% | 82.14% | -95.86× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |